SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.
Yang, Chang-Yong; Wang, Lei; Sun, Xing; Tang, Mi; Quan, Hai-Tian; Zhang, Lian-Shan; Lou, Li-Guang; Gou, Shao-Hua.
Acta Pharmacol Sin
; 2019 Jan 14.
Artigo em Inglês | MEDLINE | ID: mdl-30643210
Preclinical Pharmacokinetics of a Novel anti-c-Met Antibody-Drug Conjugate, SHR-A1403, in Rodents and Non-human Primates.
A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.